Global Leading Market Research Publisher QYResearch announces the release of its latest report “Insulin Detemir – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Insulin Detemir market, including market size, share, demand, industry development status, and forecasts for the next few years.
The Disappearing Insulin: Why Novo Nordisk’s Global Withdrawal of Levemir Is Reshaping Basal Insulin Market Dynamics
The global Insulin Detemir market is experiencing a rare and instructive phenomenon in pharmaceutical industry analysis: a clinically valued, regulatorily approved biologic therapy undergoing a managed global market exit driven not by safety concerns or efficacy failure, but by portfolio optimization economics. The market, valued at USD 5,586 million in 2025, is projected to contract to USD 2,630 million by 2032, reflecting a negative compound annual growth rate (CAGR) of -10.2% . For hospital formulary directors, health system pharmacy leaders, and diabetes care specialists, this trajectory demands urgent clinical and operational attention. The discontinuation of Levemir (insulin detemir)—announced globally by Novo Nordisk—requires the systematic migration of patients to alternative basal insulins, creating a complex transition management challenge that will define the basal insulin market through 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6606869/insulin-detemir
Product Definition: The Molecular Architecture of Insulin Detemir
Insulin Detemir is a long-acting basal insulin analog and a soluble biologic medicine manufactured through recombinant DNA expression in Saccharomyces cerevisiae followed by chemical modification. The molecular design distinguishes it from human insulin through two specific modifications: the threonine residue at position B30 is removed, and a C14 myristic fatty-acid side chain is attached to lysine at position B29. This engineered architecture achieves its prolonged action profile through a dual mechanism—self-association at the injection site forming dihexamers, and reversible albumin binding in the circulation via the fatty-acid moiety, which slows absorption and extends systemic exposure.
Commercial formulations are typically clear, colorless, aqueous injections at 100 units/mL, commonly supplied as 3 mL cartridges or pre-filled pens containing 300 units each, with excipients including glycerol, phenol, metacresol, zinc acetate, disodium phosphate dihydrate, sodium chloride, and water for injections. The product belongs to the basal insulin/long-acting insulin analog category and is mainly used for background glycemic control in type 1 and type 2 diabetes, either alone or in combination with prandial insulin, oral antidiabetic agents, or GLP-1 receptor agonists.
Industrial production requires sophisticated capabilities in recombinant expression and purification, structural modification consistency, sterile fill-finish, cold-chain handling, delivery-device compatibility, potency and impurity control, as well as pharmaceutical and clinical comparability evaluation. The manufacturing complexity is substantial: biologics require tacit knowledge, long development timelines, and massive financial investment, meaning that even when patents expire—as detemir’s core composition-of-matter patent did in 2019—competition does not automatically follow .
The Global Withdrawal Timeline: A Coordinated Market Exit
Novo Nordisk has executed a phased global withdrawal of insulin detemir that represents one of the most significant managed product discontinuations in modern diabetes care. In the United States, the company permanently withdrew Levemir from the market, removing one of only three basal insulin options available to American patients . The European Medicines Agency confirmed that affected EU presentations will be discontinued before the end of 2026 . In the United Kingdom, the Department of Health and Social Care issued formal discontinuation notices, with stock exhaustion expected by December 2026, and reissued these notices because a significant number of patients continued to use the product . In India, Novo Nordisk is phasing out insulin detemir alongside its broader portfolio of older insulin brands, including Human Mixtard—a brand generating over INR 800 crore in annual revenue—as part of a global strategy to prioritize newer, patent-protected therapies .
The clinical implications of this withdrawal are consequential. There is no direct, like-for-like switch for Levemir, and patients require careful switching and additional monitoring when transitioning to alternative insulin products . The Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes & Obesity Society have issued joint guidance on selecting and safely initiating alternative basal insulins specifically in preparation for the Levemir discontinuation .
The Clinical Differentiation That Creates Transition Complexity
Insulin detemir occupies a unique clinical niche that alternative basal insulins do not fully replicate. Among long-acting insulin analogs, detemir is the only basal insulin with a comparatively shorter duration of action, typically providing coverage for approximately 14 hours in routine clinical use, compared with insulin glargine (more than 24 hours) and insulin degludec (more than 42 hours) . This pharmacokinetic distinction has made detemir particularly valuable in specific patient populations.
Pediatric endocrinologists have relied on detemir’s flexibility to adjust overnight versus daytime insulin needs independently, especially in young children whose activity levels are unpredictable. Adolescents participating in sports have benefited from detemir’s shorter-acting profile, which helps prevent hypoglycemia during intense physical activity. For pregnant patients with diabetes, detemir’s shorter half-life allows clinicians to respond rapidly when insulin requirements shift—particularly during delivery, when insulin needs can drop sharply by up to 50% within the first 24 hours postpartum . As Dr. Florence Brown of Harvard Medical School has noted, the longer duration of glargine and degludec makes it harder to titrate during pregnancy, a clinical context where detemir’s dosing flexibility has proven especially valuable .
Market Dynamics: From Patient Initiation to Therapeutic Migration
The practical market opportunity for Insulin Detemir is no longer large-scale new patient penetration. The strategic reality for the 2026-2032 forecast period centers on three transition management dynamics: stable switching of existing patients, localized supply continuity until stock exhaustion, and refined service in markets where registrations and inventories still remain. Short-term residual demand will persist among pediatric patients, pregnancy-related use, and individuals highly attached to specific delivery devices or established treatment regimens.
However, the downstream demand pattern is unambiguously shifting from “new patient initiation” to “existing patient maintenance and therapeutic switching.” Hospitals are placing greater weight on supply continuity, reimbursement access, hypoglycemia management, dosing convenience, and training burden—factors that favor basal insulins with more stable supply outlooks and longer lifecycle visibility, particularly insulin glargine and insulin degludec. Retail and community channels are focused on post-switch glucose variability, body-weight effects, learning costs for delivery devices, and prescription refill convenience. The real downstream pattern for insulin detemir over 2026-2032 is more likely to be characterized by inventory depletion, structural substitution, and regimen migration rather than independent and sustainable market expansion.
Competitive Landscape and Supply Concentration
The competitive landscape for insulin detemir is distinctive: it is a single-supplier market. Public company websites, regulatory databases, and official product information do not show an established follow-on marketed biosimilar landscape for insulin detemir in major regulated markets, meaning supply is highly concentrated in a single operating subject—Novo Nordisk. As a result, market size, manufacturing continuity, regulatory maintenance, and commercial access are all strongly influenced by one company’s portfolio decisions.
The broader context reinforces this strategic shift. Novo Nordisk now makes over half the world’s insulin and derives far more revenue from GLP-1 receptor agonists such as Ozempic and Wegovy . Insulin detemir was a lower-margin product that competed with the company’s own patent-protected insulin degludec. The clinical and commercial focus in basal insulin continues to move toward insulin glargine, insulin degludec, and longer-duration products, leaving insulin detemir at a disadvantage in prescribing priority, dosing frequency, channel economics, and resource allocation.
Manufacturers profiled in this report:
Novo Nordisk
Market Segmentation
Segment by Type:
Reusable
Disposable
Segment by Application:
Hospital
Clinic
Home Use
Others
The Basal Insulin Ecosystem: Growth Despite Detemir’s Contraction
While the insulin detemir market contracts, the broader basal insulin and long-acting insulin analog market continues to expand, driven by the relentless growth of the global diabetes patient base. The 2025 IDF figures indicate approximately 589 million adults aged 20-79 living with diabetes worldwide, with a projection of 853 million by 2050. An estimated 9.5 million people are living with type 1 diabetes globally—a 13% increase since 2021—for whom basal insulin remains an essential, non-optional therapy . The global basal insulin market was estimated at USD 19.65 billion in 2025, with insulin glargine accounting for the largest market share due to its ability to provide 24-hour coverage with low risk of hypoglycemia .
For pharmaceutical supply chain strategists, health system pharmacy directors, and clinical endocrinology leaders, the insulin detemir market represents a case study in managing therapeutic transition at scale. The period through 2032 will require coordinated clinical switching programs, patient education initiatives, and careful glucose monitoring protocols to ensure that the withdrawal of a clinically distinct insulin analog does not compromise glycemic outcomes for the vulnerable populations—children, pregnant women, and those with type 1 diabetes—who have relied on its unique pharmacokinetic profile.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
